Browse IFI30

Summary
SymbolIFI30
Nameinterferon, gamma-inducible protein 30
Aliases IFI-30; GILT; IP30; MGC32056; IP-30; gamma-interferon-inducible lysosomal thiol reductase; interferon gamma- ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted Lysosome
Domain PF03227 Gamma interferon inducible lysosomal thiol reductase (GILT)
Function

Lysosomal thiol reductase that can reduce protein disulfide bonds. May facilitate the complete unfolding of proteins destined for lysosomal degradation. Plays an important role in antigen processing. Facilitates the generation of MHC class II-restricted epitodes from disulfide bond-containing antigen by the endocytic reduction of disulfide bonds (By similarity). Facilitates also MHC class I-restricted recognition of exogenous antigens containing disulfide bonds by CD8+ T-cells or crosspresentation (By similarity).

> Gene Ontology
 
Biological Process GO:0002474 antigen processing and presentation of peptide antigen via MHC class I
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002495 antigen processing and presentation of peptide antigen via MHC class II
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II
GO:0031647 regulation of protein stability
GO:0034341 response to interferon-gamma
GO:0042590 antigen processing and presentation of exogenous peptide antigen via MHC class I
GO:0048002 antigen processing and presentation of peptide antigen
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048147 negative regulation of fibroblast proliferation
GO:0050821 protein stabilization
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0071346 cellular response to interferon-gamma
Molecular Function GO:0016667 oxidoreductase activity, acting on a sulfur group of donors
Cellular Component GO:0005775 vacuolar lumen
GO:0043202 lysosomal lumen
> KEGG and Reactome Pathway
 
KEGG hsa04612 Antigen processing and presentation
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-913531: Interferon Signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-2132295: MHC class II antigen presentation
Summary
SymbolIFI30
Nameinterferon, gamma-inducible protein 30
Aliases IFI-30; GILT; IP30; MGC32056; IP-30; gamma-interferon-inducible lysosomal thiol reductase; interferon gamma- ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IFI30 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IFI30 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24409177Diffuse Large B-Cell LymphomaPromote immunityGILT reduces protein disulfide bonds in the endocytic compartment, exposing additional epitopes for binding to MHC class II and facilitating antigen presentation.
Summary
SymbolIFI30
Nameinterferon, gamma-inducible protein 30
Aliases IFI-30; GILT; IP30; MGC32056; IP-30; gamma-interferon-inducible lysosomal thiol reductase; interferon gamma- ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IFI30 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIFI30
Nameinterferon, gamma-inducible protein 30
Aliases IFI-30; GILT; IP30; MGC32056; IP-30; gamma-interferon-inducible lysosomal thiol reductase; interferon gamma- ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IFI30 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.290.49
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3860.919
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2130.937
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6680.467
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4140.828
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472.0580.469
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.440.605
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1930.794
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1150.513
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IFI30 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIFI30
Nameinterferon, gamma-inducible protein 30
Aliases IFI-30; GILT; IP30; MGC32056; IP-30; gamma-interferon-inducible lysosomal thiol reductase; interferon gamma- ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IFI30. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIFI30
Nameinterferon, gamma-inducible protein 30
Aliases IFI-30; GILT; IP30; MGC32056; IP-30; gamma-interferon-inducible lysosomal thiol reductase; interferon gamma- ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IFI30. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IFI30.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIFI30
Nameinterferon, gamma-inducible protein 30
Aliases IFI-30; GILT; IP30; MGC32056; IP-30; gamma-interferon-inducible lysosomal thiol reductase; interferon gamma- ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IFI30. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIFI30
Nameinterferon, gamma-inducible protein 30
Aliases IFI-30; GILT; IP30; MGC32056; IP-30; gamma-interferon-inducible lysosomal thiol reductase; interferon gamma- ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IFI30 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIFI30
Nameinterferon, gamma-inducible protein 30
Aliases IFI-30; GILT; IP30; MGC32056; IP-30; gamma-interferon-inducible lysosomal thiol reductase; interferon gamma- ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IFI30 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIFI30
Nameinterferon, gamma-inducible protein 30
Aliases IFI-30; GILT; IP30; MGC32056; IP-30; gamma-interferon-inducible lysosomal thiol reductase; interferon gamma- ......
Chromosomal Location19p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IFI30 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.